glp retatrutide (GLP-3): The Triple Agonist Peptide — Research Overview – Emerald Peptides GLP-3- RETA Research Peptide |

Side Effects Comparison# Retatrutide Side Effects# Phase 2 trial data revealed: Gastrointestinal : Nausea (24-46%), diarrhea (16-26%), vomiting (9-20%), constipation (6-16%) Heart rate : Small mean increase (2-4 bpm) potentially related to glucagon receptor activation Injection site reactions : Mild and transient Hepatic : Transient elevations in liver enzymes observed Discontinuation rate : 6-10% due to adverse events in Phase 2 The glucagon receptor component introduces a unique side effect profile compared to GLP-1-only or GIP/GLP-1 dual agonists

a) BMI % vs nausea

The safety and efficacy of these products are not guaranteed

J Biol Chem 288(20):1447614487